Arterial XXXX and @entity64 .

@entity1 @entity64 @entity101 @entity6 @entity731 @entity65
OBJECTIVES: Arterial @entity101 is, besides age, the number one risk factor for @entity64 . @entity1 with arterial @entity101 frequently present with additional coexisting vascular risk factors interacting in a complex way. MATERIAL AND METHODS: This paper reviews the benefit of antihypertensive treatment, as well as different treatment options of arterial @entity101 and their side-effects. RESULTS: @entity1 with @entity101 , but also @entity1 with so-called normal or high-normal blood pressure are at increased risk to develop @entity64 and other @entity65 . Vascular remodelling of small and large vessels provoked by arterial @entity101 is the initial step in the development of @entity731 and lipohyalinosis. Vascular remodelling can be improved or even normalized by antihypertensive treatment with angiotensin-converting-enzyme inhibitors and angiotensin-I-receptor antagonists showing the most convincing effects. Angiotensin-converting-enzyme inhibitors and angiotensin-I-receptor antagonists have the lowest rate of side-effects, however, economic restraints hinder their general application. Statins are needed to treat dyslipidaemia. They also lower blood pressure and have a synergistic effect with the above two antihypertensive components in lowering blood pressure. In @entity101 @entity1 , risk of @entity64 and other @entity65 is determined by the blood pressure level and the presence or absence of target organ damage and the interaction with other risk factors, such as cigarette smoking, dyslipidaemia, and @entity6 . These high-risk @entity1 should be treated even more aggressively than usual. CONCLUSIONS: In the vast majority of @entity1 and healthy individuals, target blood pressure should be as high as or below 120/80 mmHg to minimize the occurrence of @entity64 and other @entity65 .
